Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maartje A. Berends"'
Autor:
Marloes E. van Muijen, Sarah E. Thomas, Hans M.M. Groenewoud, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Sharon R.P. Dodemont, Else N. Kop, Maartje A.M. Berends, Marjolein I.A. Koetsier, Johannes M. Mommers, John E.M. Körver, Ron A. Tupker, Marjolein S. de Bruin-Weller, Lizelotte J.M.T. Weppner-Parren, Bas Peters, Marloes M. Kleinpenning, Astrid L.A. Kuijpers, W. Peter Arnold, Paula P.M. van Lümig, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
Publikováno v:
Acta Dermato-Venereologica, Vol 102 (2022)
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly comp
Externí odkaz:
https://doaj.org/article/e146b3b81ecf4e69ba49684069d330cc
Autor:
Selma Atalay, Juul M.P.A. van den Reek, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje M. Berends, Peter C.M. van de Kerkhof, Hans M.M. Groenewoud, Alfons A. den Broeder, Elke M.G.J. de Jong, Wietske Kievit
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 19, p adv00340 (2020)
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patien
Externí odkaz:
https://doaj.org/article/f5400933dae24130a11bded79abe9536
Autor:
Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Publikováno v:
Journal of Dermatological Treatment, 33, 5, pp. 2680-2684
Journal of Dermatological Treatment, 33, 2680-2684
Journal of dermatological treatment, 33(5), 2680-2684. Informa Healthcare
Journal of Dermatological Treatment, 33, 2680-2684
Journal of dermatological treatment, 33(5), 2680-2684. Informa Healthcare
Contains fulltext : 282879.pdf (Publisher’s version ) (Open Access) BACKGROUND: Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatm
Autor:
M.E. Otero, M.D. Njoo, J.M. Mommers, Elke M G J de Jong, P.M. Ossenkoppele, Maartje A Berends, Lieke J. van Vugt, Hans Groenewoud, Alfons A den Broeder, Juul M. P. A. van den Reek, M.I.A. Koetsier, Selma Atalay, Peter C.M. van de Kerkhof, Wietske Kievit
Publikováno v:
JAMA Dermatol
Jama Dermatology, 156, 4, pp. 393-400
Jama Dermatology, 156, 393-400
Jama Dermatology, 156, 4, pp. 393-400
Jama Dermatology, 156, 393-400
Importance Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible. Objective To investigate whether dose reduction (DR) of biologics in patients with stable psoriasis is noninferior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a6cfb2b8be0d89ef4f9c35ddfa301d6
https://doi.org/10.1001/jamadermatol.2019.4897
https://doi.org/10.1001/jamadermatol.2019.4897